Stephen G. O’Brien

13.7k total citations · 4 hit papers
43 papers, 4.5k citations indexed

About

Stephen G. O’Brien is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Stephen G. O’Brien has authored 43 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hematology, 35 papers in Genetics and 23 papers in Rheumatology. Recurrent topics in Stephen G. O’Brien's work include Chronic Myeloid Leukemia Treatments (42 papers), Chronic Lymphocytic Leukemia Research (35 papers) and Eosinophilic Disorders and Syndromes (23 papers). Stephen G. O’Brien is often cited by papers focused on Chronic Myeloid Leukemia Treatments (42 papers), Chronic Lymphocytic Leukemia Research (35 papers) and Eosinophilic Disorders and Syndromes (23 papers). Stephen G. O’Brien collaborates with scholars based in United Kingdom, United States and Switzerland. Stephen G. O’Brien's co-authors include Brian Druker, François Guilhot, Richard A. Larson, Jerald P. Radich, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Insa Gathmann, John M. Goldman and Jörge E. Cortes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Stephen G. O’Brien

42 papers receiving 4.4k citations

Hit Papers

Long-Term Outcomes of Imatinib Treatment... 2007 2026 2013 2019 2017 2007 2008 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    2017 797 citations Andreas Hochhaus, Richard A. Larson et al. New England Journal of Medicine profile →
  2. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    2007 540 citations Hagop M. Kantarjian, Francis J. Giles et al. Blood profile →
  3. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
    2008 491 citations Richard A. Larson, Brian Druker et al. Blood profile →
  4. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
    2009 444 citations Michael W. Deininger, Stephen G. O’Brien et al. Blood profile →

Peers

Stephen G. O’Brien
Michael J. Mauro United States
Mary Beth Rios United States
Shu Tamura Japan
Eric Bleickardt United States
Susan O’Brien United States
Charles Chuah Singapore
Jaspal Kaeda United Kingdom
H. Kantarjian United States
Ron Paquette United States
Susan Branford Australia
Michael J. Mauro United States
Stephen G. O’Brien
Citations per year, relative to Stephen G. O’Brien Stephen G. O’Brien (= 1×) peers Michael J. Mauro

Countries citing papers authored by Stephen G. O’Brien

Since Specialization
Citations

This map shows the geographic impact of Stephen G. O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen G. O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen G. O’Brien more than expected).

Fields of papers citing papers by Stephen G. O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen G. O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen G. O’Brien. The network helps show where Stephen G. O’Brien may publish in the future.

Co-authorship network of co-authors of Stephen G. O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen G. O’Brien. A scholar is included among the top collaborators of Stephen G. O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen G. O’Brien. Stephen G. O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clark, Richard E., Jane F. Apperley, Dragana Milojković, et al.. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology. 6(7). e375–e383. 116 indexed citations
2.
Hochhaus, Andreas, Richard A. Larson, François Guilhot, et al.. (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine. 376(10). 917–927. 797 indexed citations breakdown →
3.
Clark, Richard E., Jane F. Apperley, Dragana Milojković, et al.. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology. 4(7). e310–e316. 81 indexed citations
4.
Clark, Richard E., Jane F. Apperley, Christopher Pocock, et al.. (2016). Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. Blood. 128(22). 938–938. 6 indexed citations
5.
O’Brien, Stephen G., Sarah Adams, Letizia Foroni, et al.. (2014). Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. Blood. 124(21). 517–517. 24 indexed citations
6.
Kantarjian, Hagop M., Richard A. Larson, François Guilhot, et al.. (2009). Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 115(3). 551–560. 86 indexed citations
7.
Larson, Richard A., Brian Druker, François Guilhot, et al.. (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111(8). 4022–4028. 491 indexed citations breakdown →
8.
9.
10.
Coutre, Philipp le, Francis J. Giles, Jane F. Apperley, et al.. (2007). Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.. Blood. 110(11). 471–471. 8 indexed citations
11.
Boddy, Alan V., Julieann Sludden, Melanie Griffin, et al.. (2007). Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia. Clinical Cancer Research. 13(14). 4164–4169. 22 indexed citations
12.
O’Brien, Stephen G. & Michael W. Deininger. (2003). Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in Hematology. 40(2 Suppl 2). 26–30. 36 indexed citations
13.
Takayama, Nobuyuki, Norihide Sato, Stephen G. O’Brien, Yasuo Ikeda, & Shinichiro Okamoto. (2002). Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology. 119(1). 106–108. 119 indexed citations
14.
Druker, Brian, Stephen G. O’Brien, Jörge E. Cortes, & Jerald P. Radich. (2002). Chronic Myelogenous Leukemia. Hematology. 2002(1). 111–135. 274 indexed citations
15.
Edwards, John, et al.. (2001). Imatinib for chronic myeloid leukaemia: A NICE mess [1] (multiple letters). The Lancet. 358(9296). 1902–1903. 3 indexed citations
16.
Stark, G & Stephen G. O’Brien. (2001). An update on chronic myeloid leukaemia. Clinical Medicine. 1(5). 354–357. 2 indexed citations
17.
O’Brien, Stephen G.. (1997). 12 Autografting for chronic myeloid leukaemia. Baillière s Clinical Haematology. 10(2). 369–388. 4 indexed citations
18.
Rule, Simon, David G. Savage, Stephen G. O’Brien, et al.. (1996). Intermediate‐dose busulphan before autografting for advanced‐phase chronic myeloid leukaemia. British Journal of Haematology. 94(4). 694–698. 5 indexed citations
19.
Spencer, Andrew, Stephen G. O’Brien, & John M. Goldman. (1995). OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA. British Journal of Haematology. 91(1). 2–7. 26 indexed citations
20.
Marks, David I., et al.. (1994). Orthotopic cardiac transplantation for dilated cardiomyopathy after allogeneic bone marrow transplantation. Clinical Transplantation. 8(1). 23–26. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Mauro Breakdown of academic impact, for papers by Mary Beth Rios Breakdown of academic impact, for papers by Shu Tamura Breakdown of academic impact, for papers by Eric Bleickardt Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Charles Chuah Breakdown of academic impact, for papers by Jaspal Kaeda Breakdown of academic impact, for papers by H. Kantarjian Breakdown of academic impact, for papers by Ron Paquette Breakdown of academic impact, for papers by Susan Branford
Rankless by CCL
2026